



Health Care Inspectorate - Pharmaceutical Affairs and Medical Technology

CERTIFICATE NUMBER: NL/H 17/1013229

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER^{1, 2}

Part 1

Issued following an inspection in accordance with :

Art. 111(5) of Directive 2001/83/EC as amended

The competent authority of Netherlands confirms the following:

The manufacturer: **Katwijk Chemie B.V.**

Site address: **Snijderstraat 6, KATWIJK ZH, 2222BA, Netherlands**

Is an active substance manufacturer that has been inspected in accordance with Art. 111(1) of Directive 2001/83/EC transposed in the following national legislation:

Art. 100 of the Medicines Act

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on **2017-02-02**, it is considered that it complies with :

- The principles of GMP for active substances³ referred to in Article 47 of Directive 2001/83/EC .

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact the issuing authority.

¹ The certificate referred to in paragraph 111(5) of Directive 2001/83/EC and 80(5) of Directive 2001/82/EC, shall also be required for imports coming from third countries into a Member State.

² Guidance on the interpretation of this template can be found in the Help menu of EudraGMDP database.

³ These requirements fulfil the GMP recommendations of WHO.



Part 2

Manufacture of active substance. Names of substances subject to inspection :

Calcium Valproate(en) / Calcium Valproaat(nl)
Deferiprone(en) / Deferiprone(nl)
Divalproex Sodium(en) / Divalproex Sodium(nl)
Ethosuximide(en) / Ethosuximide(nl)
Magnesium Pemoline(en) / Magnesium Pemoline(nl)
Magnesium Valproate(en) / Magnesium Valproaat(nl)
Oxaprozin(en) / Oxaprozin(nl)
Pemoline(en) / Pemoline(nl)
Phenylethylacetylurea(en) / Phenylethylacetylurea(nl)
Phenytoin(en) / Phenytoine(nl)
Phenytoin Calcium(en) / Phenytoine Calcium(nl)
Phenytoin Sodium(en) / Phenytoin Sodium(nl)
Phthalylsulfacetamide(en) / Phthalylsulfacetamide(nl)
Sodium Valproate(en) / Natrium Valproate(nl)
Sulfacetamide(en) / Sulfacetamide(nl)
Sulfacetamide Sodium(en) / Sulfacetamide Natrium(nl)
Valdisoval(en) / Valdisoval(nl)
Valproic Acid(en) / Valproine Zuur(nl)
Valpromide(en) / Valpromide(nl)
XANTHOPTERIN(en)

2017-02-14



Name and signature of the authorised person of the
Competent Authority of Netherlands

Ing. Mos van Berlo
Health Care Inspectorate - Pharmaceutical Affairs and
Medical Technology
Tel: +31 88 1205000
Fax +31 88 1205001